Allmän barnvaccination mot humant papillomvirus för flickor, en cost- benefit analys.
Cost- benefit analysisHumant papillomvirusHälsoekonomiLivmodershalscancerVaccinationCost-benefit analysisHuman papilloma virusHealth EconomicsCervical cancerVaccination
Introduction: Every year about 450 women in Sweden are diagnosed with cervical cancer, almost 200 die and thousands undergo surgery because of cell changes in the cervix. A HPV infection can lead to cervical cancer and therefor costs for the society. The implementation of a vaccination program against HPV is a way to avoid these costs. Aim: The study aimed to calculate the economic impact of the HPV- vaccination program for children in Sweden through a cost-benefit analysis. Method: In this analysis, status quo was compared with non-administration of the HPV-vaccine for the selected cohort of ten-years-old girls in Sweden. A cost-benefit analysis was used to determine the net present value of the vaccination program for children. Results: The results indicated that the vaccination program against HPV would save the society about 182 million SEK for the specified cohort of 50220 women during their lifetime. Discussion: Many uncertainties existed in the analysis due to assumptions regarding measurement and valuation of the effects. The willingness to pay was an uncertain variable that was used in the calculation that can decrease the net present value. Despite vaccination, screening is still required to ensure that early stages of cervical cancer are found and treated. Screening was excluded from the analysis; this could affect the net present value. A booster dose was not included in the calculation and could as well have a negative impact on net present value. Conclusion: The interpretation of the cost-benefit analysis is that the HPV- vaccination program for children could be seen as a viable investment in Sweden, since the savings exceeded the cost by more than 182 million SEK.